Asparaginase induces selective dose- and time- dependent cytotoxicity, apoptosis, and reduction of NFκB expression in oral cancer cells
dc.contributor.author | Borges, Gabriel Álvares | |
dc.contributor.author | Elias, Silvia Taveira | |
dc.contributor.author | Araujo, Tassiana Souza De | |
dc.contributor.author | Souza, Paula Monteiro | |
dc.contributor.author | Nascimento‐filho, Carlos Henrique Viesi | |
dc.contributor.author | Castilho, Rogerio M. | |
dc.contributor.author | Squarize, Cristiane H. | |
dc.contributor.author | Magalhães, Pérola De Oliveira | |
dc.contributor.author | Guerra, Eliete Neves Silva | |
dc.date.accessioned | 2020-05-05T19:36:10Z | |
dc.date.available | WITHHELD_13_MONTHS | |
dc.date.available | 2020-05-05T19:36:10Z | |
dc.date.issued | 2020-05 | |
dc.identifier.citation | Borges, Gabriel Álvares ; Elias, Silvia Taveira; Araujo, Tassiana Souza De; Souza, Paula Monteiro; Nascimento‐filho, Carlos Henrique Viesi ; Castilho, Rogerio M.; Squarize, Cristiane H.; Magalhães, Pérola De Oliveira ; Guerra, Eliete Neves Silva (2020). "Asparaginase induces selective dose- and time- dependent cytotoxicity, apoptosis, and reduction of NFκB expression in oral cancer cells." Clinical and Experimental Pharmacology and Physiology 47(5): 857-866. | |
dc.identifier.issn | 0305-1870 | |
dc.identifier.issn | 1440-1681 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/154950 | |
dc.description.abstract | Asparaginase is fundamental to the treatment of haematological malignancies. However, little has been studied on the effects that asparaginase could exert on solid tumours. Thus, this study aimed to evaluate the effects of asparaginase on an oral carcinoma cell line. The cytotoxicity of asparaginase in SCC- 9 (tongue squamous cell carcinoma) and HaCaT (human keratinocyte) cell lines was evaluated with MTT cell viability assay. The cells were treated with asparaginase at 0.04, 0.16, 0.63, 1.0, 1.5, 2.5, and 5.0 IU/mL. Dose- response curves and IC50 values were obtained and the Tumour Selectivity Index (TSI) was calculated. The effect of asparaginase on procaspase- 3 and nuclear factor κB (NFκB) expression was evaluated with western blot because it was reported that the overexpression of NFκB has been shown to contribute to tumour cell survival, proliferation, and migration. Caspase 3/7 staining was performed to identify cell death using flow cytometry. Effective asparaginase concentrations were lower for SCC- 9 cells when compared to HaCaT cells. The cytotoxicity results at 48 and 72 hours were significantly different for SCC- 9 cells. The TSI indicated that asparaginase was selective for the tumour cells. A decrease in procaspase- 3 and NFκB protein levels was observed in SCC- 9 cells. Furthermore, asparaginase resulted in significant apoptosis after 48 and 72 hours. Based on these results, asparaginase was cytotoxic in a dose- and time- dependent manner, induces apoptosis, and reduces NFκB expression in oral cancer cells. These results encourage further studies on the effectiveness of this enzyme as a treatment for solid tumours, especially head and neck cancer. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | asparaginase | |
dc.subject.other | NFκB | |
dc.subject.other | oral cancer cells | |
dc.subject.other | apoptosis | |
dc.title | Asparaginase induces selective dose- and time- dependent cytotoxicity, apoptosis, and reduction of NFκB expression in oral cancer cells | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | |
dc.subject.hlbsecondlevel | Physiology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/154950/1/cep13256.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/154950/2/cep13256_am.pdf | |
dc.identifier.doi | 10.1111/1440-1681.13256 | |
dc.identifier.source | Clinical and Experimental Pharmacology and Physiology | |
dc.identifier.citedreference | Xia Y, Shen S, Verma IM. NF- kappaB, an active player in human cancers. Cancer Immunol Res. 2014; 2 ( 9 ): 823 - 830. | |
dc.identifier.citedreference | Lorenzi PL, Llamas J, Gunsior M, et al. Asparagine synthetase is a predictive biomarker of L- asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther. 2008; 7 ( 10 ): 3123 - 3128. | |
dc.identifier.citedreference | Lorenzi PL, Reinhold WC, Rudelius M, et al. Asparagine synthetase as a causal, predictive biomarker for L- asparaginase activity in ovarian cancer cells. Mol Cancer Ther. 2006; 5 ( 11 ): 2613 - 2623. | |
dc.identifier.citedreference | Yu M, Henning R, Walker A, et al. L- asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer. J Cell Mol Med. 2012; 16 ( 10 ): 2369 - 2378. | |
dc.identifier.citedreference | Abakumova OY, Podobed OV, Karalkin PA, Kondakova LI, Sokolov NN. Antitumor activity of L- asparaginase from Erwinia carotovora against different human and animal leukemic and solid tumor cell lines. Biochem (Mosc) Suppl Ser B Biomed Chem. 2012; 6 ( 4 ): 307 - 316. | |
dc.identifier.citedreference | Taylor CW, Dorr RT, Fanta P, Hersh EM, Salmon SE. A phase I and pharmacodynamic evaluation of polyethylene glycol- conjugated L- asparaginase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2001; 47 ( 1 ): 83 - 88. | |
dc.identifier.citedreference | Kim K, Jeong JH, Lim D, et al. L- Asparaginase delivered by Salmonella typhimurium suppresses solid tumors. Mol Ther Oncolytics. 2015; 2: 15Â 007. | |
dc.identifier.citedreference | Kyriakidis DA, Tsirka SA, Tsavdaridis IK, Iliadis SN, Kortsaris AH. Antiproliferative activity of L- asparaginase of Tetrahymena pyriformis on human breast cancer cell lines. Mol Cell Biochem. 1990; 96 ( 2 ): 137 - 142. | |
dc.identifier.citedreference | Knott SRV, Wagenblast E, Khan S, et al. Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 2018; 554 ( 7692 ): 378 - 381. | |
dc.identifier.citedreference | Tardito S, Chiu M, Uggeri J, et al. L- Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of beta- catenin- mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets. 2011; 11 ( 8 ): 929 - 943. | |
dc.identifier.citedreference | Zhang B, Dong LW, Tan YX, et al. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer. 2013; 109 ( 1 ): 14 - 23. | |
dc.identifier.citedreference | Avramis VI. Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res. 2012; 32 ( 7 ): 2423 - 2437. | |
dc.identifier.citedreference | Lanvers- Kaminsky C. Asparaginase pharmacology: challenges still to be faced. Cancer Chemother Pharmacol. 2017; 79 ( 3 ): 439 - 450. | |
dc.identifier.citedreference | Ji Y, Li L, Tao Q, et al. Deprivation of asparagine triggers cytoprotective autophagy in laryngeal squamous cell carcinoma. Cell Death Differ. 2017; 101 ( 12 ): 4951 - 4961. | |
dc.identifier.citedreference | Wolf JS, Chen Z, Dong G, et al. Waes. IL (interleukin)- 1alpha promotes nuclear factor- kappaB and AP- 1 - induced IL- 8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res. 2001; 7: 1812 - 1820. | |
dc.identifier.citedreference | Kalavrezos N, Scully C. Mouth cancer for clinicians. Part 2: epidemiology. Dent Update. 2015; 42 ( 4 ): 354 - 358, 358- 359. | |
dc.identifier.citedreference | Moreira J, Tobias A, O’Brien MP, Agulnik M. Targeted therapy in head and neck cancer: an update on current clinical developments in epidermal growth factor receptor- targeted therapy and immunotherapies. Drugs. 2017; 77 ( 8 ): 843 - 857. | |
dc.identifier.citedreference | Shrivastava A, Khan AA, Khurshid M, Kalam MA, Jain SK, Singhal PK. Recent developments in L- asparaginase discovery and its potential as anticancer agent. Crit Rev Oncol Hematol. 2016; 100: 1 - 10. | |
dc.identifier.citedreference | Fung MKL, Chan GC. Drug- induced amino acid deprivation as strategy for cancer therapy. J Hematol Oncol. 2017; 10 ( 1 ): 144. | |
dc.identifier.citedreference | Zhang B, Fan J, Zhang X, et al. Targeting asparagine and autophagy for pulmonary adenocarcinoma therapy. Appl Microbiol Biotechnol. 2016; 100 ( 21 ): 9145 - 9161. | |
dc.identifier.citedreference | Liu T, Zhang L, Joo D, Sun SC. NF- kappaB signaling in inflammation. Signal Transduct Target Ther. 2017; 2: e17023. | |
dc.identifier.citedreference | Kim JH, Gupta SC, Park B, Yadav VR, Aggarwal BB. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)- kappaB and NF- kappaB- regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol Nutr Food Res. 2012; 56 ( 3 ): 454 - 465. | |
dc.identifier.citedreference | Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, Gutking JS. Molecular crosstalk between the NFkB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia. 2006; 8 ( 9 ): 733 - 746. | |
dc.identifier.citedreference | Igelmann S, Neubauer HA, Ferbeyre G. STAT3 and STAT5 activation in solid cancers. Cancers (Basel). 2019; 11 ( 10 ): 1428. | |
dc.identifier.citedreference | Zhang W, Liu Y, Li YF, Que Y, Yang X, Peng L. Targeting of survivin pathways by YM155 inhibitis cell death and invasion in oral squamous cell carcinoma cells. Cell Physiol Biochem. 2016; 38: 2426 - 2437. | |
dc.identifier.citedreference | Duarte VM, Han E, Veena MS, et al. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the nuclear factor kB pathway. Mol Cancer Ther. 2010; 9 ( 10 ): 2665 - 2675. | |
dc.identifier.citedreference | Panosyan EH, Wang Y, Xia P, et al. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors. Mol Cancer Res. 2014; 12 ( 5 ): 694 - 702. | |
dc.identifier.citedreference | Tardito S, Uggeri J, Bozzetti C, et al. The inhibition of glutamine synthetase sensitizes human sarcoma cells to L- asparaginase. Cancer Chemother Pharmacol. 2007; 60 ( 5 ): 751 - 758. | |
dc.identifier.citedreference | Pelucchi C, Bosetti C, Galeone C, La Vecchia C. Dietary acrylamide and cancer risk: an updated meta- analysis. Drugs. 2015; 136 ( 12 ): 2912 - 2922. | |
dc.identifier.citedreference | Xu F, Oruna- Concha MJ, Elmore JS. The use of asparaginase to reduce acrylamide levels in cooked food. Food Chem. 2016; 210: 163 - 171. | |
dc.identifier.citedreference | WHO. List of Essencial Medicine, 2015; 19th Edition: http://www.who.int/selection_medicines/committees/expert/20/EML_2015_FINAL_amended_AUG2015.pdf?ua=1. Accessed February 2019. | |
dc.identifier.citedreference | Ali U, Naveed M, Ullah A, et al. L- asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): a novel approach to target ALL. Eur J Pharmacol. 2016; 771: 199 - 210. | |
dc.identifier.citedreference | Zheng W, Ren H, Ke X, et al. PEG- asparaginase in BFM- 90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma. Chin J Cancer Res. 2017; 29 ( 1 ): 66 - 74. | |
dc.identifier.citedreference | Bu S, Yuan F, Wei X, et al. L- asparaginase- based regimen as a first- line treatment for newly diagnosed nasal type extranodal natural killer cell/T- cell lymphoma. Exp Ther Med. 2016; 11 ( 6 ): 2437 - 2445. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.